https://www.sciencedaily.com/releases/2025/10/251019120503.htm
“People with advanced lung or skin cancer who received a COVID-19 mRNA vaccine
within 100 days of beginning immunotherapy lived considerably longer than those
who did not, according to new research.
Scientists from the University of Florida and the University of Texas MD
Anderson Cancer Center describe this as a milestone in more than a decade of
work developing mRNA-based treatments that activate the body's immune defenses
against cancer. Building on an earlier UF study, the results represent an
important step toward creating a universal cancer vaccine capable of enhancing
the effects of immunotherapy.
The analysis, which examined medical records from over 1,000 MD Anderson
patients, is still preliminary. However, if upcoming randomized clinical trials
confirm these results, the impact on cancer care could be profound.
"The implications are extraordinary — this could revolutionize the entire
field of oncologic care," said senior researcher Elias Sayour, M.D., Ph.D., a
UF Health pediatric oncologist and the Stop Children's Cancer/Bonnie R. Freeman
Professor for Pediatric Oncology Research. "We could design an even better
nonspecific vaccine to mobilize and reset the immune response, in a way that
could essentially be a universal, off-the-shelf cancer vaccine for all cancer
patients."
Jeff Coller, Ph.D., a leading mRNA expert at Johns Hopkins University, noted
that the findings highlight yet another way Operation Warp Speed (the U.S.
government's rapid COVID-19 vaccine initiative) continues to benefit lives in
"unique and unexpected ways."
"The results from this study demonstrate how powerful mRNA medicines truly are
and that they are revolutionizing our treatment of cancer," Coller said.”
Via Susan ****
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
